Research programme: antibody therapeutics - Genmab/Roche
Latest Information Update: 03 Sep 2009
At a glance
- Originator Genmab; Roche
- Class Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer; Inflammation; Respiratory tract disorders; Vascular disorders
Most Recent Events
- 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
- 26 Aug 2009 Preclinical development is ongoing in Europe
- 06 Mar 2008 Preclinical development is ongoing